Benda Pharmaceutical (OTCBB: BPMA) came out with some extraordinary news after market close Monday. The Company says that its trials were met with such overwhelming enthusiasm that physicians present immediately placed orders for 16,000 vials, effectively buying out all of its available supplies in just one day; these sales are expected to total $3.8 million. (See More Below) Benda Pharmaceutical (BPMA) Website:
http://www.bendapharma.com
Press Release Benda Pharmaceutical (OTCBB: BPMA) Today announced after market close that results following clinical trials, presented at its national forum on "Gene Therapy for Tumors" on September 9, 2007, were met with such overwhelming enthusiasm that physicians present immediately placed orders for 16,000 vials, effectively buying out all available product in just one day; when realized, these sales are expected to total $3.8 million. Prior to Benda's acquisition of
SiBiono, Benda dramatically enhanced the marketing and distribution of Gendicine and anticipates that SiBiono will earn $5.0 million in net income in 2007 -- a 600% immediate improvement. To see this press release in it's entirety click here.
Overview Benda Pharmaceutical, Inc., a China-based pharmaceutical company, is a pure play on explosive Chinese pharmaceutical spending and the global search for a cancer cure. Benda produces conventional and Traditional Chinese Medicines, as well as Genedicine, the world's first commercialized gene
therapy medicine for the treatment of cancer.
BPMA Investor Highlights - The Chinese currently spend about $12 per capita on pharmaceuticals, as compared to $340 per capita in the U.S. As the Chinese population ages and become wealthier, the already large Chinese pharmaceutical market is poised for continued explosive growth.
- According to a recent report by McKinsey, Chinese healthcare spending will grow from $32 billion in 2004 to approximately $323 billion by 2025, or at a compound annual growth rate of 11.6%.
- By 2010, the Chinese pharmaceutical market will
be the 5th largest in the world.
Financial Forecast - Benda anticipates 2007 revenue of approximately $40.7 million, compared to $15.9 million in 2006 -- a 156% increase.
- The Company anticipates 2007 net income of approximately $7.3 million, compared to approximately $2.3 million in 2006 -- a 217% increase.
- 2007 anticipated revenue of $40.7 million is expected to jump to $76.2 million in 2008.2007 anticipated net income of $7.3 million to more than double to $17.8 million in 2008.
Recent News and Press Releases Benda Takes Major Step Toward Qualification for NASDAQ Listing by Establishing Independent Board Benda Unveils Dramatically Enhanced Gendicine(R) Distribution System, Provides Update on Number of Patients Treated to Date
Financials Approximate as of September 24, 2007 Market Cap:
218.2 Million Outstanding Shares: 99.2 Million 52 Low / High: $0.41 / $3.00 Price: $2.20
Copyright SmallCapReview. All rights reserved. SCR is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our web site and individual reports released to the public through this web site, e-mail or any other means of transmission are not to be regarded as
investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility. Particularly Small-Caps and OTC-BB stocks. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our web site or within our reports
is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. SCR may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act of 1933, Section 17(b), SCR will disclose in it's disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the SCR web site. SCR
has been compensated two thousand dollars by a third party (APS) for its efforts in presenting the Benda Pharmaceutical profile on its website and distributing to its database of subscribers. SCR may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report. The Reader should verify all claims and do their own due diligence before investing in any securities mentioned. Investing in small-cap securities is speculative and carries a high degree of risk. We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov and/or the National Association
of Securities Dealers (NASD) at: http://www.nasd.com. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.
| 